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ScienceDirectDiseases where fibrosis plays a major role accounts for
enormous morbidity and mortality and yet we have very little in
our therapeutic arsenal despite decades of research and
clinical trials. Our understanding of fibrosis biology is primarily
built on data generated in conventional mono-culture or co-
culture systems and in vivo model systems. While these
approaches have undoubtedly enhanced our understanding of
basic mechanisms, they have repeatedly failed to translate to
clinical benefit. Recently, there had been a push to generate
more physiologically relevant platforms to study fibrosis and
identify new therapeutic targets. Here we review the state-of-
the-art regarding the development and application of 3D
complex cultures, bio-printing and precision cut slices to study
pulmonary, hepatic and renal fibrosis.
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Introduction
Fibrosis is the replacement of functional tissue architec-
ture with excess fibrous connective tissue, leading to a
reduction in organ function and ultimately organ failure
and death. Fibrosis can affect all tissues in the body and
therefore is a ubiquitous problem that contributes mas-
sively to morbidity and mortality worldwide [1]. While
fibrosis is the common end-point for a wide range of
diseases, the underlying aetiologies and mechanisms
can be either core or organ specific, and in the majority
of cases remain ill-defined/idiopathic [2]. There are only
two approved anti-fibrotic therapies (Pirfenidone andwww.sciencedirect.com Nintedanib) and both are licenced exclusively for the
treatment of patients with mild-moderate Idiopathic Pul-
monary Fibrosis (IPF) [3]. There is therefore an urgent
unmet need to develop new anti-fibrotic therapies for use
in other fibrotic diseases.
The global burden of fibrosis and lack of treatment
options has led to the development of a wealth of experi-
mental approaches to illuminate the underlying cellular
and molecular mechanisms driving fibrosis, with the goal
to identify new therapeutic targets [4]. The most com-
monly utilised model systems use human or rodent cells
(both immortalised cell lines and primary cells) in con-
ventional 2D submerged mono-cultures or co-cultures
exposed to exogenous stimuli (e.g. Transforming Growth
Factor-b1 (TGF-b1), matrix stiffness) to drive fibrogen-
esis/fibrosis in vitro [5]. Routinely these in vitro models are
complemented by in vivo animal models of fibrosis, in a
range of species from invertebrates to large mammals,
with the most commonly employed experimental system
being mouse models. While these models have undoubt-
edly provided valuable insights into our understanding of
fibroblast biology and aspects of disease progression,
these data have frequently failed to yield the necessary
clinical benefit. Currently the probability of a drug pro-
gressing from Phase I to approval is <10% despite large
investments in drug development [6,7]. One prominent
explanation is flawed preclinical research, in which the
use and outcome of animal models or non-physiological
human systems is used to bridge the translational gap to
the clinic.
Fibrosis is a tightly regulated and dynamic process that
involves a wide range of cell types, numerous cyto-
kines/chemokines/growth factors and multiple cell–
cell and cell–matrix interactions that drive concurrent
biological processes in the complex microenvironment
of human tissue. Widely utilised animal models and
conventional 2D mono-culture and co-culture systems
[8,9] fail to recreate the complex interactions seen in
human tissue and thus mechanisms driving fibrosis
need to be interrogated in more representative, com-
plex human tissue systems. In this review, we will
describe the state-of-the-art of the quest to develop
more physiologically relevant in vitro/ex vivo cell cul-
ture systems to model fibrosis, focussing particularly on
exciting recent advances in complex 3D cell culture
models, bio-printing and precision cut slice (PCS)
methodologies (Figure 1).Current Opinion in Pharmacology 2019, 49:95–101
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Models of organ fibrosis.
A summary of the seven main research methodologies used to model fibrotic disease, along with the main advantages and disadvantages of each
method. The breadth of models are ranked by the proximity of the model to the patient disease. Created with BioRender.com.Spheroids
Single or multicellular spheroids can be formed as hang-
ing droplet cultures under gravity or in cell-repellent or
ultra-low attachment plates. This methodology allows the
rapid production of numerous spheres for studying dis-
ease biology, drug screening and toxicity studies.
To this end, hanging droplet microtissues comprising
human hepatocyte, hepatic stellate cells (HSC) and Kupf-
fer cell (KC) cell lines were engineered to model drug-
induced fibrosis, whilst addition of lipopolysaccharide was
used to evoke an inflammatory response [10]. Leite et al.
created 3D liver spheroids from HepaRG cells and pri-
mary HSC to concurrently model fibrogenesis and hepa-
totoxicity. The organoids retained cell-specific markers,
cytochrome p450 expression and albumin production for
21 days. Hepatotoxic compounds; allyl alcohol, paraceta-
mol or methotrexate induced HSC activation, inflamma-
tion and ECM gene expression [11].Current Opinion in Pharmacology 2019, 49:95–101 HSC rapidly transdifferentiate on plastic, whereas, HSC
spheroid monocultures maintain a quiescent phenotype
in culture until transferred to plastic where they rapidly
activate. HSC spheroids were used to delay HSC acti-
vation and deliver siRNA’s targeting yes-associated pro-
tein (YAP), a transcriptional transducer of mechanical
stress, to blunt HSC activation [12]. This proof-of-
concept study identifies a system where quiescent
HSC can be modified, to identify proteins important
for HSC activation.
Tissue mimics
Nugraha et al. developed a 3D-dextran hydrogel model to
artificially construct a renal tubule and model epithelial-
myofibroblast crosstalk, under normal and disease-
induced conditions. HCK-8 spheroids cultivated in
hydrogel form tight junctions and acquire cellular polar-
ity. Quiescent primary human myofibroblasts were then
overlaid in a second gel layer, encapsulating the tubulewww.sciencedirect.com
Novel methodologies to study fibrosis Oakley et al. 97structure. Nephrotoxin exposure promoted loss of E-
cadherin, myofibroblast proliferation and induction of
fibrosis genes [13]. Pirfenidone blunted this response,
highlighting the translational relevance of this model.
Cell lines can be easily genetically modified to modulate
protein expression or monitor biological responses in real-
time. Here, HCK-8 cells expressed E-cadherin-GFP as a
‘biosensor’ of epithelial differentiation.
A 3D space of Disse mimic was created from primary rat
hepatocytes cultured on collagen coated plates, separated
from a heterogeneous layer of sinusoidal endothelial cells,
HSC and KC by a detachable polyelectrolyte multilayer
(PEM). Normal PEM or PEMs with increasing mechani-
cal stiffness (21–43 kPa) were used to assess the influence
of substrate elasticity on HSC activation in the context of
physiological cell:cell crosstalk [14]. Akin to 2D and 3D
cultures, increasing mechanical stiffness accelerated HSC
activation and fibrogenic phenotype.
Decellularised tissue
Decullularised or acellular tissue scaffolds from normal or
fibrotic organs that are repopulated with single or multi-
ple cell lines or primary cells have been developed over
the past decade to study fibrosis and perform drug feasi-
bility studies. Standardised perfusion and immersion
methods to generate and manipulate decellularised tissue
scaffolds, the clinical applications and limitations of the
technology have been recently reviewed [15–18].
For fibrosis, Booth et al. reported that the native tissue
structure, stiffness and ECM composition is preserved
in acellular tissue scaffolds created from normal or
fibrotic human lung. Interestingly, lung fibroblasts cul-
tured in normal scaffolds have low aSMA expression
whereas myofibroblast markers are significantly
increased when fibroblasts are cultured in fibrotic scaf-
folds, a response that is independent of TGFb [6]. A
follow-up study revealed that these acellular lung scaf-
folds populated  with iPSC could be exploited to study
fibrosis biology [19]. In liver, Pinzanni‘s group opti-
mised a retrograde perfusion protocol to decellularise
human liver tissue and fashion acellular cubes that
retain the native ECM composition and structure
[20]. Hepatocyte and HSC cell lines seeded into these
scaffolds were preserved in culture and the cellularised
scaffolds were successfully xenografted into immuno-
competent mice.
He et al. recently described the optimal conditions to
generate decellularised rat kidney to preserve struc-
ture, collagen, fibronectin, glycosaminoglycans and
laminin. Interestingly, this group reseeded the kidney
scaffold by directly injecting either primary renal cell
or bone marrow derived mesenchymal stromal cells
(MSCs) through the vasculature, and then maintained
flow through the scaffold to aid the recellularizationwww.sciencedirect.com process. Histological analysis of the recellularized
tissue revealed glomerular-like structures, which
express both epithelial and endothelial markers, sug-
gesting that micro-flow may facilitate the repopulation
process [21].
Tissue stiffness and ECM composition can modulate
myofibroblast behaviour [22]. To dissect the contribu-
tion of these environmental cues to pericytes-myofi-
broblast differentiation, human pericytes were grown
on hydrogels permeated with soluble decellularised
normal or fibrotic lung matrix, bioengineered to have
tuneable mechanical properties. In short-term cultures,
aSMA expression was significantly induced in peri-
cytes cultured on IPF matrix compared to normal
matrix, and this activation was supressed by Ninteda-
nib. Matrix stiffness was the dominant regulator of
pericyte activation, independent of matrix composition
or TGFb stimulation. However, prolonged exposure to
ECM or fibrotic stimuli was sufficient to drive pericyte
differentiation [23].
Bioprinting
Bioprinting allows rapid and highly reproducible auto-
mated fabrication of biomimetic tissue models. Cellular
composition, environmental substrates and soluble fac-
tors collectively termed ‘bioinks’ can be customised to
create bespoke 3D culture models with bioactive matri-
ces. Fusion of bioprinting and bioengineering technolo-
gies provide an opportunity to manufacture ‘modulatable
systems’ where the physical properties of ECM, for
example, stiffness or crosslinking can be chemically or
photo-activated/inactivated. For further details of Bioinks
and bioprinting see Ref. [24].
A bioprinted human liver comprising cryopreserved pri-
mary human hepatocytes, HSC and umbilical vein endo-
thelial cells was developed by Norona et al. to model drug
or TGFb induced tissue injury, inflammation and fibrosis
[25]. In a follow-up study, KC were integrated into the
model to evaluate parenchymal-macrophage-mesenchy-
mal cell signalling during drug induced liver injury and
fibrosis [26]. Recently, Ma et al. bioprinted HepG2 cells
suspended in decellularized matrix and used digital light
processing to photo-crosslink the matrix scaffold to mimic
mechanical stiffness in the normal (0.5 kPa) and diseased
liver (15 kPa). Although this system has been developed
to evaluate the role of matrix rigidity on liver cancer cell
growth and migration, the technology could be modified
to study fibrosis [27].
Whilst the field is in its infancy and application has mainly
focused on regenerative medicine for many organs, the
field is rapidly evolving. In the future, it could have great
value in illuminating mechanisms of tissue fibrosis and for
anti-fibrotic drug discovery.Current Opinion in Pharmacology 2019, 49:95–101
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Complex 3D models are useful drug discovery tools but
fail to fully recapitulate the cellular heterogeneity and
physiological components of the native tissue. Precision
cut slices (PCS) produced from either normal or diseased,
rodent or human tissue, offer a more faithful model to
study fibrosis [28–30]. Importantly, human PCS are a
valuable tool to validate discoveries in other preclinical
models and test emerging anti-fibrotic medicines in a
clinically relevant system.
Normal mouse precision cut kidney slices (PCKS) cul-
tured in 80% oxygen have increased inflammatory gene
expression within 3 hours, whilst fibrosis gene expression
was elevated by 96 hours. Treatment with LY2109761, a
TGFb receptor inhibitor, blunted the fibrogenic response
confirming that spontaneous fibrosis was in part TGFb-
dependant [31]. Using this system, successful myofibro-
blast-specific targeting of an anti-fibrotic IFNg-peptide
conjugate (PPB-PEG-IFNg) limited TGFb-induced
fibrogenic gene expression and collagen deposition
[32], providing evidence that peptide therapies can pen-
etrate tissue slices and exert biological effects.
To model interstitial kidney fibrosis, PCKS were gener-
ated from unilateral ureteral obstruction (UUO) rats.
Nordic extracellular matrix neo-epitopes of collagen for-
mation (P1NP) and collagen degradation (C1M and
C3M) were significantly raised in the media of UUO
PCKS compared to sham controls PCKS [33]. Active
TGFb was detectable in cultured fibrotic but not normal
PCKS, suggesting establishment of a positive fibrogenic
signalling feedback loop.
A feasibility study by Stribos et al. revealed that TGFb
stimulation induced fibrosis in normal human PCKS
without compromising viability or metabolic activity
[34]. The anti-fibrotic actions of Butaprost, a prostaglan-
din E2 receptor agonist, were shown in both mouse and
human fibrotic PCKS. Butaprost did not affect PCKS
metabolism or viability and drug engagement was con-
firmed by attenuation of TGFb/SMAD signalling [35],
corroborating a common mechanism of drug action
between rodents and humans.
To study cellular changes driving interstitial lung disease
(ILD), normal human PCLuS without ILD, were chal-
lenged with a cocktail of pro-fibrogenic and pro-inflam-
matory factors; TGFb, TNFa, PDGFAB, and lysopho-
sphatidic acid [36]. In culture, the fibrogenic cocktail
promoted alveolar thickening, induced fibrosis and
inflammatory gene expression and stimulated the secre-
tion and deposition of ECM proteins, without effecting
tissue viability or mitochondrial function. This method-
ology provides a useful tool system to interrogate the
molecular and cellular mechanisms driving the pathogen-
esis of ILD/IPF.Current Opinion in Pharmacology 2019, 49:95–101 Lehmann et al. used normal and disease murine primary
alveolar epithelial type II (pmATII) and human PCLuS
to identify the cellular targets of Pirfenidone and Ninte-
danib. Both drugs inhibited collagen and fibronectin
expression in pmATII and PCLuS. However, only Nin-
tedanib supressed changes in epithelial plasticity, sug-
gesting that Nintedanib targets multiple cell types within
the fibrogenic niche [37].
Fibrosis is both a progressive and reversible disease.
Hansen et al. modelled ECM dynamics in rat fibrotic
lung slices (fPCLuS) and reported that disease-relevant
biomarkers; P1NP, C1M, P3NP,C3M and ELM7 (an
elastin degradation marker) are increased in cultured
fPCLuS but blunted by an MMP or phosphodiesterase
inhibitor [38]. Anti-fibrotic actions of an ALK5 inhibitor
and Nintedanib have been reported in fPCLuS created
from chronic bleomycin injured mice, consistent with
previous in vitro and in vivo studies [39]. Moreover, in
agreement with observations in 2D human bronchial
epithelial cultures, caffeine was shown to block epithelial
activation of TGFB1, limiting fibrogenic gene expression
and collagen production in fPCLuS [40].
Mechanistic studies in IPF fibroblasts cultured under 3D
macromolecular conditions [41] and in human IPF
PCLuS [42] revealed that matrix production was regu-
lated by a TGF-b1-mTORC1-4E-BP1 dependant, PI3K
independent, signalling axis. Proteomic studies on IPF
PCLuS revealed that novel inhibitors of this pathway
attenuated the secretion of matrisome factors and the
biomarker P1NP.
TGF-b1/PDGF-b1 co-stimulation induces a robust fibro-
genic response in normal PCLS without causing toxicity
[43]. A number of anti-fibrotic compounds showing effi-
cacy in 2D cultures or animal models have been validated
in rodent and/or human precision cut liver slices (PCLS)
[43–45]. Recently, Galunisertib, a TGF-b receptor type I
kinase inhibitor, was shown to block TGFb1 signalling,
fibrogenic gene expression and ECM production in
rodent and human PCLS [46]. Whilst targeting integrin
alpha 11 (ITGA11) using Erismodegib reduced expres-
sion of fibrogenic genes and transcriptional targets of
integrin-hedgehog signalling in hPCLS [47].
The PI3K/mTOR pathway is activated in multiple fibro-
tic diseases and is likely a common mechanism of fibrosis
therefore testing pharmacological inhibitors of this path-
way in multiple organs systems will have clinical value.
The PI3K/mTOR inhibitor Omipalisib supressed AKT
phosphorylation and fibrosis gene expression in normal or
diseased (cholestatic mdr2/ mice or mice with
NAFLD) PCLS. Omipalisib also reduced fibrogenic
responses in normal and cirrhotic human PCLS. How-
ever, Omipalisib caused toxicity in cirrhotic human PCLS
and intestinal slices [48], highlighting the importance ofwww.sciencedirect.com
Novel methodologies to study fibrosis Oakley et al. 99assessing drugs in advanced disease and investigating
potential off target effects in other organs.
Typically, PCLS are cultured in high oxygen concentra-
tions to offset the detrimental effects of tissue hypoxia.
Recently, a bioreactor technology that creates flow
through the PCLS was described to maintain functional
PCLS — retaining all liver cell types and metabolic
activity under normoxic conditions for six-days [49].
Histological fibrosis, release of soluble ECM markers
and expression of fibrogenic genes could be induced in
normal rodent and human PCLS by co-stimulation with
TGFb1/PDGFb1, a response that is attenuated by a
number of antifibrotic drugs. Fibrogenesis was self-sus-
taining in bioreactor cultured rat fPCLS but limited by
ALK5 inhibitor therapy. This bioreactor model was also
used to demonstrate hepatoprotective and anti-fibrotic
activities of the ammonia scavenger; ornithine phenyla-
cetate in lipid-loaded and/or hyperammonaemia-treated
human PCLS [50].
Modelling different aetiologies of liver disease
A recent study demonstrated the feasibility of modelling
the metabolic syndrome of liver disease by culturing
rodent PCLS in supraphysiological levels of sugars, fat
(palmitic acid) and insulin for 48 hours. Histological stea-
tosis, elevated triglyceride levels and an increase in
lipogenic gene expression were observed in disease-
induced PCLS, consistent with pathology in patients with
metabolic liver disease [51]. The Chokshi group
reported that PCLS treated with ethanol induced changes
in mitochondrial morphology indicative of alcohol-
induced hepatic injury, however, fibrosis was not investi-
gated [29]. Whilst, Page et al. used ethanol stimulated rat
PCLS to validate mechanistic studies showing that etha-
nol evokes epigenetic changes in HSC to regulate elastin
production. Interestingly, PCLS treated with acetate,
ethanol’s stable metabolite, failed to evoke the same
response [52].
Conclusion
Considerable research efforts have driven the develop-
ment of more complex systems to study fibrosis mecha-
nisms and test anti-fibrotic therapies. Current strategies to
recreate disease-specific pathologies [29,50,51,52] will
complement the arsenal of existing research models,
creating a breadth of disease models to test drug utility
and efficacy. As complex 3D fibrosis models become more
established, advanced molecular imaging for example,
second-generation harmonics, RNA-sequencing or prote-
omic biomarker screens will become routine assays for
anti-fibrotic drug discovery.
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